CLINICAL ROLE -
Role of the Clinical Pharmacist in Multiple Myeloma Management
Read More
Breast Cancer Insights: Updates from the 2023 ASCO Annual Meeting
Heather Moore, CPP, PharmD, recaps key topics from the 2023 ASCO meeting surrounding breast cancer treatment.
Utilizing Clinical Pathways in Ovarian Cancer
Ryan Haumschild, PharmD, MS, MBA, provides insights surrounding the utilization of PARP inhibitors and clinical pathways in ovarian cancer treatment.
The Use of Combination Therapies in the Frontline Setting for CLL
Expert, Zahra Mahmoudjafari, PharmD, BCOP, DPLA shares insights on the expanding treatment landscape for CLL.
Pharmacist Appreciation
Tim Whitten, BSPharm, MBA, CEO & President of Taiho Oncology Inc discusses the critical impacts of pharmacists across the health care landscape.
Sponsored by Taiho Oncology Inc.
The Impact of New Data Released at ASH 2022 on the Treatment Landscape of CML and Ph+ ALL
Neal Dave, PharmD, and Brandon Dyson, PharmD, BCOP, BCPS, share insights regarding the treatment landscape for patients with CML and Ph+ ALL.
Hemophilia A Management: A Review of Prophylaxis Options
Prophylactic treatment is critical to treatment management for patients diagnosed with hemophilia A.
The Evolving Role of BTK Inhibitors in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Medical experts detail the current and evolving roles of BTK inhibitors in treatment of patients with relapsed/refractory mantle cell lymphoma.
Future Directions in Treatment of Chronic Lymphocytic Leukemia (CLL) with BTK Inhibitors
Experts in hematology/oncology share key insight on the treatment of CLL, including the use of BTK inhibitors and the critical role of pharmacists in disease management.
The Evolving Treatment Landscape in CLL: Updates from ASH 2021
Considerations regarding updates to chronic lymphocytic leukemia treatment algorithms based on novel and emerging therapies presented at the ASH 2021 annual meeting.
Treatment Innovations in Waldenstrom Macroglobulinemia
Pharmacist and provider perspective on BTK inhibitors for Waldenstrom macroglobulinemia.
Treatment Innovations in Relapsed/Refractory Marginal Zone Lymphoma
Shared insight on unmet needs and recent innovations in the management of marginal zone lymphoma in the relapsed/refractory setting.
On the Shelf Video Series
Joanna Lewis, PharmD, MBA, discusses practical considerations when selecting over-the-counter medications to treat common conditions pharmacists are often asked about and highlights some recommended medications from the Pharmacy Times’ OTC Guide
Second-line Maintenance Therapy in Ovarian Cancer: PARP Inhibitors
Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, discuss the importance of utilizing PARP inhibitors as second-line maintenance therapy in ovarian cancer and share valuable clinical insights.
Targeted Therapy Treatment Innovations in AML
Optimizing Patient Outcomes with Prescription Discount Programs
Innovations in the Treatment of Chronic Lymphocytic Leukemia
A discussion on advancements and updates in the treatment of CLL, including the latest research presented at the 2021 American Society of Clinical Oncology Virtual Meeting.
Advancements and Updates in the Treatment Options for CLL
Advancements in the Treatment and Management of HER2-Positive Early Breast Cancer
Advancements and Updates in Therapies for CLL
Opportunities to Improve Pharmacy Workflow in the Preparation of Levothyroxine
Proper Dosing of Anticoagulants in CAD/PAD
Management of Chemotherapy-Induced Nausea and Vomiting
Implications of Potential Heparin Shortage
Pharmacists' Knowledge of In-Home Drug Testing
The Cardiovascular Benefits of GLP-1 Agonists
Economic Burden of ABSSSI
Patient Selection and Safety with TNF Inhibitors
Understanding Axial Spondyloarthritis
Biosimilars and Pharmacy Interchangeability